Physician profile
Daniil Libman
NPI 1669924965
$11,203.12
in general payments reported to CMS, 2019-2025
33 companies · $3,961 in 2025
The $3,961 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $864 · 2022: $1,573 · 2023: $2,075 · 2024: $2,730 · 2025: $3,961.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,750 · Education: $15.57.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,750.17 |
| Education | $15.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,057.82 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,594.84 | 2021-2025 | Xifaxan, Trulance, Plenvu |
| Aimmune Therapeutics, INC. | $660.36 | 2023-2025 | Zenpep |
| Qol Medical, LLC | $656.84 | 2022-2025 | Sucraid, Sucraid |
| Pfizer INC. | $586.19 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $513.20 | 2021-2025 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $451.61 | 2022-2025 | Tremfya, Stelara, Simponi |
| Madrigal Pharmaceuticals | $392.06 | 2024-2025 | Rezdiffra, Resmetirom |
| Intercept Pharmaceuticals, INC. | $355.42 | 2021-2025 | Ocaliva |
| Braintree Laboratories, INC. | $298.88 | 2022-2025 | Sutab |
| Ironwood Pharmaceuticals, INC | $279.98 | 2022-2024 | Linzess |
| Ardelyx, INC. | $264.20 | 2022-2025 | Ibsrela |
| Nestle Healthcare Nutrition INC. | $248.53 | 2022-2023 | |
| Ipsen Biopharmaceuticals, INC | $211.52 | 2025 | Iqirvo |
| Vivus LLC | $210.49 | 2023-2025 | Qsymia, Pancreaze |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $210.20 | 2023-2025 | Rebyota, Clenpiq |
| Lilly USA, LLC | $198.58 | 2023-2025 | Omvoh, Zepbound |
| Celltrion USA INC. | $161.75 | 2024-2025 | Vegzelma, Zymfentra |
| Janssen Scientific Affairs, LLC | $127.26 | 2024 | Stelara |
| Genzyme Corporation | $114.75 | 2023-2025 | |
| Gilead Sciences, INC. | $110.49 | 2025 | |
| Evoke Pharma, INC. | $87.43 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $67.10 | 2023-2025 | Dupixent |
| Phathom Pharmaceuticals, INC. | $63.61 | 2024-2025 | Voquezna |
| Orphalan INC | $61.76 | 2024 | Cuvrior |
| Biocon Biologics INC | $46.32 | 2025 | Yesintek |
| Boston Scientific Corporation | $41.71 | 2024 | Watchman Flx |
| Celgene Corporation | $41.70 | 2022-2023 | Zeposia |
| Blueprint Medicines Corporation | $23.51 | 2025 | Ayvakit |
| Merck Sharp & Dohme LLC | $18.69 | 2022 | |
| Sanofi Pasteur INC. | $18.05 | 2023 | |
| Novo Nordisk INC | $14.71 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.56 | 2023 | Cyltezo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniil Libman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.